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Abstract Urticaria is a common, mast cell-driven disease 
presenting with wheals or angioedema or both. In the last 
years, urticaria has increasingly attracted notice to 
clinicians and researchers, last but not least inspired by the 
approval of omalizumab, an anti-IgE antibody, for urticaria 
treatment. There is wide consensus on the clinical 
classification based on duration and elicitation. However, 
the pathogenesis is incompletely understood. This review 
summarizes current guidelines for the management and 
novel insights in the pathogenesis of urticaria with special 
focus on their impact on clinical praxis. The classification 
of urticaria subgroups is mainly based on clinical criteria: 
acute and chronic urticaria (CU). Chronic urticaria 
comprises both chronic spontaneous urticaria (CSU) and 
chronic inducible urticaria (CIndU) that includes physical 
and non-physical urticarias. Recent research focused on 
characterizing the role of cells and mediators involved in 
the pathogenesis of urticaria, identifying the mechanisms 
of mast cell activation, and investigating underlying 
autoimmune processes in chronic spontaneous urticarial. 
Currently, non-sedating antihistamines and omalizumab, 
an antiimmunoglobulin E antibody, are recommended for 
the therapy of chronic urticaria, as both exhibit a favorable 
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efficacy and safety profile. Novel therapeutic strategies aim 
at specifically targeting cells and mediators involved in the 
pathogenesis of urticaria. 
Keywords Angioedema . Mastcell . Histamine . 
Omalizumab . Urticaria 
Abbreviations 
ACE Angiotensin converting enzyme 
ACU Acquired cold urticaria 
AE Angioedema 
AIU Autoimmune urticaria 
ASST Autologous serum skin test 
ChU Cholinergic urticaria 
CIndU Chronic indicible urticaria 
CRTH2 Chemoattractant receptor–homologous 
molecule expressed on TH2 cells 
CU Chronic urticaria 
CSU Chronic spontaneous urticaria 
DPU Delayed pressure urticaria 
Ig Immunoglobuline 
IL Interleukin 
PG Prostaglandin 
SU Solar urticaria 
TNF Tumor necrosis factor 
    
 
TPO Thyroperoxidase 
UAS Urticaria activity score 
Urticaria is a common disease as in acute form affects 20% 
of the general population and chronic urticaria (CU) up to 
5% [1].Recent progress in the therapy ofchronic urticaria 
with the approval of omalizumab has extensively 
stimulated clinical and basic research in the field. In this 
review, we highlight novel insights in the pathogenesis and 
management of urticaria which we selected because of 
their potential impact on daily practice. 
Current Definitions 
Urticaria is defined as the sudden development of transient 
hives (wheals) and angioedema or both [2]. A wheal is 
characterized by a circumscribed superficial edema of the 
skin, mostly surrounded by a bright red erythema and 
associated with a strong itching or burning sensation. In 
urticaria, wheals develop within several minutes and have 
a transient nature inasmuch as the skin returns to its normal 
appearance within 1–24h.Angioedema presents aspainful 
orburning,non-itchy, and less well-demarcated edema of 
the deep dermis and subcutis, or mucous membranes. 
Usually, angioedema appears as skin-colored or slightly 
red swellings and, compared to wheals, they slowly 
develop and may persist for several days [2]. In addition to 
the skin and adjacent mucosa, the gut is typically affected 
by certain types of angioedema, e.g., hereditary 
angioedema. Angioedema of the pharynx or larynx may be 
life threatening through the risk of asphyxiation [3]. 
Clinical Classification of Urticaria 
Current classifications consider both duration and causes/ 
triggers of urticaria [2, 4]. Acute urticaria is defined by a 
repeated appearance of wheals with or without angioedema 
over a period of up to 6 weeks, whereas the recurrence of 
lesions over more than 6 weeks is considered as chronic 
[2]. In 10–20% ofthe cases, angioedema may be the first 
and often only manifestation of urticaria. Approximately 
60% of the patients with chronic spontaneous urticaria 
(CSU) report on angioedema episodes [5]. For a 
comprehensive review on the differential diagnosis of 
angioedema without urticaria, see a very recent review in 
this journal [3]. 
A recent study reported a high frequency of systemic 
signs and symptoms such as joint pain or swelling (55.3%), 
headache/fatigue (47.6%), flushing (42.7%), wheezing or 
breathlessness (30.1%), gastrointestinal complaints 
(26.2%), and palpitations (9.7%) in two thirds of adult 
patients with CSU that are probably under-recognized in 
daily practice [6]. Interestingly, the number of organs 
involved did not correlate with serum tryptase levels [6]. 
Depending on whether the skin lesions appear 
spontaneously or can be induced by a specific trigger, 
urticaria is classified as either CSU or chronic inducible 
urticaria (CIndUs) [2, 4]. Within the group of CIndUs, 
symptomatic dermographism/urticaria factitia, cold- and 
heat-induced urticarias, delayed pressure urticaria, solar 
urticaria, and vibratory angioedema are defined as physical 
urticarias. Non-physical CIndUs include cholinergic 
urticaria, contact urticaria, and aquagenic urticaria [4]. 
Chronic Spontaneous Urticaria 
A nationwide epidemiological study revealed an annual 
prevalence of CSU ranging from 0.02% in 2002 to 0.38% 
in 2013 and an incidence of 0.10–1.50 per 1000 person-
years in Italy [7]. For both prevalence and incidence rates, 
female patients outnumbered males: 0.48 versus 0.23% and 
1.6 versus 0.8 per 1000 person-years, respectively [7]. 
Obesity, anxiety, dissociative and somatoform disorders, 
and malignancies were associated with an increased risk to 
develop CSU [7]. Among patients with CSU, two thirds 
reacted to physical triggers [8]. CSU is considered a mast 
cell-driven disease triggered by infections, food or drug 
intolerance, activation of the coagulation cascade, genetic 
disposition, or autoimmunity [9]. Both type I (IgE 
mediated) and type II (autoantibodies of IgG or IgM type) 
hypersensitivity reactions have been associated with CSU 
[9]. The autologous serum skin test (ASST: intradermal 
injection of patients own serum) is often used as screening 
for autoimmune CSU since some studies found positive 
reactions morefrequently inCSU patientscomparedwith 
healthy controls, atopic individuals, or CIndUs [9]. In 
order to test the presence and functional activity of anti-
IgE and antiIgE receptor autoantibodies, additional 
diagnostic tests with ELISA or Western blot and basophil 
activation test have been recommended [10]. 
Chronic Inducible Urticarias 
Symptomatic Dermographism 
Urticarial dermographism is the most frequent form of 
physical urticaria with an estimated prevalence of 5% of 
the general population [11]. Symptomatic dermographism 
is an exaggerated response to a relatively minor stroking 
pressure, rubbing, or scratching, e.g., induced by trouser 
waistbands, cuffs, or collars [12]. Usually, the wheals 
disappear within minutes after cessation of the causative 
stimulus. Recently, an instrument for assessing provocation 
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threshold levels in patients with symptomatic 
dermographism has been developed (Fig. 1) [13]. 
Acquired Cold Urticaria 
Acquired cold urticaria (ACU), the second most frequent 
type of physical urticaria, is characterized by lesions 
developing upon exposure to cold air, liquids, or solids and 
occurs more frequently in women than men [4, 14]. 
Extensive cold contact, e.g., diving in cold water, may 
provoke systemic symptoms such as dyspnea, hypotension, 
and loss of consciousness in addition to wheals resembling 
anaphylaxis and may lead to death [15]. A retrospective 
study revealed a mean temperature threshold of 13.7 ± 6.0 
°C; range 26–4 °C (Fig. 1) [14]. Siebenhaar et al. 
subclassified primary and secondary ACU, without or with 
underlying cause, respectively [16]. ACU has 
beenassociated with viral, bacterial,and parasitic infections 
as well as cryoglobulinemia with monoclonal IgG or mixed 
types of IgG/IgM and IgG/IgA [16]. There are case reports 
on ACU associated with hymenoptera stings, food and 
drug intolerance, low C1-inhibitor and C4 as well as 
altered chemokine levels [16]. Atypical variants of ACU 
are summarized in Table 1 [16, 17]. 
Heat-Induced Urticaria 
In heat urticaria, a very rare variant of physical urticaria, a 
circumscribed wheal and flare reaction develops 
immediately after local heat exposure to the skin. Atypical 
familial as well as pediatric cases have been published. The 
wheals usually persist for 1–3 h [18]. 
Delayed Pressure Urticaria 
Delayed pressure urticaria (DPU) presents with 
angioedemalike swellings at areas of the skin and mucosa 
exposed to pressure. Classical wheals do not occur in DPU. 
Painful swellings, itching, or burning occur several hours 
after exposure to vertical pressure and may persist for 
hours, sometimes longer than 24 h. Triggers are carrying 
backpacks or bags with shoulder straps, sitting on hard 
chairs, tight shoes, carrying heavy bags by hand. DPU 
often coexists with CSU or other types of physical 
urticaria. DPU should be distinguished from symptomatic 
dermographism in which friction induces wheals without 
delay and of short duration, e.g., lesions under the belt or 
bra [18]. 
Solar Urticaria 
Inmost patients with solar urticaria (SU), the trigger is a 
UV-A light, while provocation by visible or UV-B light is 
less frequent. SU is rare: 0.08% among urticaria patients, 
2.3% of the patients with acute sun-induced skin problems. 
Female predominance, an association with atopy but not 
with skin pigmentation type as well as concomitant other 
types of CU have been reported in SU [19]. Upon 
activation by light, serum or dermal factors, that have not 
been further specified, have been assumed to cause mast 
cell degranulation [20]. Omalizumab may be helpful in 
some SU patients [21, 22]. 
Cholinergic Urticaria 
Cholinergic urticaria (ChU) is triggered by a sudden 
increase of body core temperature, e.g., induced by 
exercise/exertion, fever, hot baths or showers, emotional 
stress, hot or spicy foods, and drinks. Its prevalence is 
higher in young adults and peaks in winter in some patients 
[23, 24]. Some authors found an association with atopy and 
bronchial hyperresponsiveness [23, 25, 26]. A distinct sign 
of ChU are extensive flares of short-lived, pruritic, tiny (up 
to 5–6 mm) wheals, so-called pinpoint wheals. Recent 
studies demonstrated a lack of acetylcholinesterase in 
eccrine gland epithelial cells and a decreased expression of 
the cholinergic receptor M3 (CHRM3), probably due to an 
autoimmune reaction to eccrine sweat glands and/or 
Fig. 1 Urticarial dermographism 
induced by a dermographometer 
on the back of patient (left) and a 
wheal provoked by cold exposure 
in a patient with acquired cold 
urticaria (4 °C, right) 
    
 
acetylcholine receptors, resulting in increased tissue levels 
of acetylcholine that stimulates mast cells degranulation 
[18, 27]. In addition to cholinergic agents, such as 
acetylcholine, histamine, allergenic components of sweat, 
serum factors, poral occlusion of eccrine sweat glands, and 
anhidrosis have been accused to induce ChU [28]. 
Japanese groups have suggested a ChU classification based 
on clinical characteristics: (1) conventional sweat allergy 
type, (2) follicular type with a positive ASST, (3) ChU 
with palpebral angioedema, and (4) ChU with 
acquiredanhidrosis and/or hypohidrosis [27–31]. 
Vibratory Angioedema 
This extremely rare variant of physical urticaria typically 
presents with angioedema immediately developing after 
exposure to local vibration [18]. Vibratory angioedema 
induced by snoring or dental procedures has been observed 
[32, 33]. Recently, a novel missense variant in ADGRE2 
has been reported as the basis of autosomal dominant 
vibratory urticaria [34]. 
Contact Urticaria 
Upon contact with the provoking substance, contact 
urticaria immediately manifests with wheals that disappear 
within a few hours. The wheals are provoked by either 
IgE-mediated or non-immunologic mechanisms. The 
urticarial reaction is usually confined to the area of 
exposure, but may spread and cause systemic symptoms, 
which might be life threatening in IgE-mediated allergic 
contact urticaria [35, 36]. Repeated contact with the 
causative substance may lead to the development of 
dermatitis/eczema, either by non-immunological/irritant or 
by IgE-mediated allergic reactions. Common eliciting 
factors include foods, plant components (esp. sap, leaves, 
etc.), latex, drugs, cosmetics, industrial chemicals, animal 
products, or textiles [37]. Thus, contact urticaria should be 
recognized as an occupational skin disease, e.g., in food 
processing workers, healthcare professionals, and 
hairdressers. 
Aquagenic Urticaria 
Aquagenic urticaria is a rare variant of CIndUs and shares 
features of both physical urticarial and contact urticaria. 
Patients exhibit folliculocentric wheals of 1–3 mm 
diameter and surrounding larger flares within 20–30 min 
after skin contact to water, sweat, or tears [38]. The short-
lived wheals usually occur on the trunk and upper arms, 
while palms and soles are spared. Aquagenic urticaria has a 
high impact on the quality of life. Based on a recent 
comprehensive review, there are atypical clinical 
presentations, with urticarial reactions depending on the 
salinity of the water, and exaggerated reactions in patients 
with associated systemic diseases or decreased thickness of 
the stratum corneum following epilation or exposure to 
organic solvents [38]. 
Urticaria Impairs Quality of Life 
In acute urticaria, pruritus had the highest negative impact 
on the patients’ quality of life [39]. Patients with acute 
urticaria were shown to be more satisfied with their lives 
and used emotion-focused coping and sought social 
support for emotional and instrumental reasons to a greater 
degree than patients with chronic urticaria [40]. A recent 
study on CU patients reported a mean total score of 36 (0–
100) using the Chronic Urticaria Quality of Life 
Questionnaire [41]. The items with the highest mean scores 
were nervousness and sense of shame because of lesions 
[41]. In CU patients, mental health and physical 
impairment, activity levels on and off work as well as 
anxiety and depression were comparable with those of 
patients with moderate and severe psoriasis [42]. 
For the assessment of disease activity, the patients’ 
healthrelated quality oflifeand the disease impactondaily 
activities, a number of detailed questionnaires have been 
developed [43–45]. For daily routine, the Urticaria Activity 
Score (UAS) 7 is recommended which assesses the number 
of wheals and itch intensity on seven consecutive days 
(maximum score per day: six; zero = no symptoms, three = 
Atypical cold urticaria Diagnostic criterion 
Atypical acquired cold 
urticaria 
Cold contact stimulation test negative 
Delayed cold urticaria Wheals develop up to 24 h after testing 
Cold-dependent 
dermographism 
Induced upon stroking of precooled skin 
Cold-induced cholinergic 
urticaria 
Induced by exercise in cold environment 
Systemic atypical cold 
urticaria 
Wheals plus systemic signs and symptoms upon exposure to distinct 
environmental cold conditions 
Table 1 Differential diagnosis 
of atypical cold urticaria 
(modified from [17, 18]) 
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severe symptoms) [43, 44]. The UAS7 might be amended 
by other disease activity parameters, e.g., the size of the 
largest wheal [45]. CU severity assessed by the UAS7 was 
shown to correlate with the impact on quality of life, sleep 
and daily activity interference, presence of angioedema, 
and diphenhydramine use [46]. 
Diagnostic Procedures and Differential Diagnoses 
Current guidelinesof urticaria management recommend a 
lean diagnostic work-up that focuses on the examination of 
clinical signs and assessment of symptoms associated with 
the urticarial rush and/or angioedema (Fig. 2, Table 2). 
The spectrum of differential diagnoses of acute and 
chronic urticarial is broad and involves hereditary and 
acquired diseases with urticarial rashes and/or angioedema 
of heterogeneous pathogenic mechanisms, summarized in 
Table 2. For daily practice, an algorithm guiding to 
differentiate urticaria with/without angioedema from 
bradykinin-mediated angioedema (hereditary, acquired, 
ACE-inhibitor induced) and interleukin-1 driven 
autoinflammatory diseasesmight behelpful [69]. 
Pathogenesis 
Although urticaria is a common disease, its pathogenesis is 
poorly understood. Current urticaria research focuses on 
three topics: (1) to characterize the cells and mediators 
involved, (2) to identify the mechanisms of mast cell 
activation, and (3) to investigate (auto)immune processes 
associated with CSU. Here, we will provide a selection of 
previous published work that might be important to our 
understanding of urticaria and developing novel 
therapeutic strategies. 
Cells and Mediators Involved in Urticaria Pathogenesis 
Redness, swelling, and itching of the pathognomonic 
wheals are the clinical correlate of vasodilatation, 
increased vascular permeability with leakage of fluid into 
the tissue, and stimulation of sensory nerve endings 
resulting upon activation, degranulation, and release of 
vasoactive substances by dermal mast cells. Mast cells 
contain a multitude of electro-dense granules with 
preformed and preactivated mediators, including effector 
mediators such as histamine, cytokines, and chemokines 
[70]. Their release precedes the generation of arachidonic 
acid metabolites, e.g., prostaglandin D2 (PGD2) and 
Fig. 2 Diagnostic work-up of 
urticaria with/without 
angioedema 
 
 
  
 
  
 
  
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
 
  
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
leukotriene E4 (LTE4), and platelet activation factor (PAF) 
[71]. Among mediators synthesized by mast cell such as 
tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-4, IL- 
5, IL-6, IL-8, IL-16, CCL-2, CCL-3, and RANTES, 
transglutaminase (TG) 2 has been identified in the skin and 
peripheral blood of CSU patients [72]. These mediators 
may act as chemoattractants for eosinophils, neutrophils, 
and T cells. Indeed, urticaria skin harbors a mixed 
perivascular infiltrate consistent of monocytes, eosinophils, 
basophils, and mainly CD4+ T cells. Cytokines initiating T 
helper (Th) 2 
 
Wheal >24 h, 
leukocytoklastic vasculitis 
Normocomplementemic 
+    
Hypocomplimentemic 
Autoimmune diseases 
+  + [48] 
Bullous pemphigoid +  − [49] 
Autoantibodies to bullous 
pemphigoid antigens 
BP180, BP230 
Systemic lupus 
erythematosus 
(SLE) 
+  + [50, 51] 
Antinuclear antibodies 
(ANA), Increased risk of 
SLE in CSU (14.6) 
Autoinflammatory 
diseases 
+ (+) + [52–54] 
Interleukin 1-mediated 
Cryopyrin-associated 
periodic 
syndrome (CAPS) 
+   [55] 
Cryopyrin NLRP3 gene 
mutations 
Familial cold 
autoinflammatory 
syndrome (FCAS) 
+   Cold urticaria, fever, 
arthritis 
Muckle-Wells syndrome 
(MWS) 
+   Deafness, amyloidosis 
Chronic infantile 
neurological, 
cutaneous and articular 
syndrome (CINCA) 
+   Polyarthritis, chronic 
meningitis, fever 
Schnitzler syndrome +   [56] 
Monoclonal IgM 
gammopathy 
Neutrophilic dermatoses +  (+) [57, 58] 
Peripheral blood and skin 
neutrophilia 
Sweet syndrome +    
Eosinophilic dermatoses    [59] 
Skin eosinophilia, flame 
figures 
Eosinophilic dermatitis +    
Wells’ syndrome 
Infectious/parasitic diseases 
+    
Arthropod reactions + (+)   
Viral exanthema +  (+) [60] 
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Drug induced    [61] 
Beta-lactam-antibiotics + (+)  IgE mediated 
NSAID + (+)  COX-1 inhibitors 
Muscle relaxants + (+)   
Platin salts + (+)   
Taxans + (+)   
Table 2 (continued) 
O
t
her organs Urticarial Angioedema
 involved rash 
 
Polymorphic eruption of 
pregnancy 
+   [62] 
Angioedema  + 
 
[63, 64] 
Complement C1-inhibitor 
quantity or function and C4 
decreased 
Hereditary  + + Angioedema of respiratory and 
gastrointestinal tract 
Acquired  + +  
Angiotensin-converting 
enzyme (ACE) inhibi- 
tors 
Angiotensin (AT) receptor 
blockers 
 + + Bradykinin mediated 
Anaphylaxis + + + [65–67] 
Specific IgE 
Mastocytosis    [68] 
Serum tryptase, skin, and bone 
marrow biopsy 
Cutaneous (+)  −  
Systemic (+)  +  
 
immune response such as IL-33, IL-25, and thymic stromal 
lymphopoietin (TSLP) along with IL-4 and IL-5 are 
present in lesional skin [73]. This observation together 
with previous reports on the expression of INF-γ and TNF-
α [74] suggest a mixed Th2/Th1 immune response. 
Cholinergic urticaria was reported to be associated with a 
atopic predisposition in 57% of the patients, in whom high 
Erlangen atopy scores corresponding to a distinct atopic 
predisposition of the skin were linked to high severity and 
impact on quality of life [75]. Several other mediators such 
as vascular endothelial growth factor, matrix 
metalloproteinase-9, and IL-6 have been found to be 
elevated in the peripheral blood of CSU patients [76–78]. 
However, whether these phenomena are specific or part of 
a general inflammatory milieu needs to be investigated. 
Recent research hasfocused on a role ofbasophils in 
urticaria. Both peripheral blood basopenia and altered 
basophil FcεRI function have been documented in CU 
patients [79]. Interval improvements of disease severity in 
CSU patients were associated with increased basophil 
numbers and IgE-mediated histamine release [80]. The 
reduced expression of the chemoattractant receptor–
homologous molecule expressed on TH2 cells (CRTH2) on 
basophils and eosinophils in CSU patients compared with 
healthy controls has been assumed a result of an ongoing 
PGD2 stimulation [81]. In the sera of CSU patients, 
increased IL-31 levels have been detected. IL-31 is 
   
    
 
released by basophils and may stimulate basophil 
chemotaxis and activate IL-4 and IL-13 release [82]. The 
increased expression of CD63 on basophils found in CSU 
patients correlated with allergic sensitization, serum 
autoreactivity, and basophil reactivity [83]. Interestingly, a 
paradoxic downregulation of FcεRI/anti-FcεRI/ anti-IgE 
triggered histamine release from basophils has been 
documented in CU patients [84]. Serum of patients with 
active CSU was shown to suppress basophil FcεRI activity, 
even when IgE and IgG were depleted [85]. Whether the 
alterations of basophils in urticaria are pathogenic or 
secondary events is currently under investigation. 
In CSU patients, eosinophilia has been observed in 
lesional skin and may persist in non-lesional skin. This 
observation, together with microvascular changes and 
increased mast cell numbers, suggests that non-lesional 
skin is primed for further whealing [86]. Both major basic 
protein and eosinophil peroxidase may induce histamine 
release from human mast cells [87]. A further role of 
eosinophils in CU has been proposed in the activation of 
the coagulation system due to their tissue factor expression 
[88]. 
Mast Cell Activation 
In up to 40% of the patients with CSU, autoantibodies 
directed against the α-chain of the high affinity IgE 
receptor (FcεRI) and/ or IgE of the complement fixing 
subtypes IgG1 and IgG3 have been found [89]. 
Autoantibodies binding to their target results in 
complement activation, subsequent C5a formation that 
binds to the C5a receptor on mast cells leading to their 
activation and degranulation [90]. Since a diagnostic test 
measuring functionally active autoantibodies has not yet 
been made available, the diagnosis of autoimmune urticaria 
(AIU) is still obscure [9]. Interestingly, chemokines such 
as CCL17, CCL26, and CCL27 were significantly 
increased in patients with AIU in comparison to other 
forms of CU and correlated with disease severity [91]. 
Insights in the intracellular signal transduction pathways 
might elucidate new therapeutic targets. Recently, it has 
been shown that upon an activation of the β- and γ-chain of 
the FcεRI, immunoreceptor tyrosine-based activation 
motifs (ITAMs) are phosphorylated, which associate with 
Srcfamily protein tyrosine kinases, such as Syk. The 
deactivation is regulated by signal regulatory proteins 
containing inhibitory motifs (ITIMs) that recruit SHIP 1 
and 2 which dephosphorylate the ITAMs [84]. In CU, 
altered levels of SHIP 1 and SHIP2 have been found [92]. 
In patients with non-steroidal antiinflammatory drug 
(NSAID)-induced urticaria/angioedema, significant 
associations of polymorphisms in three key genes, involved 
in mast cell activation including Syk, have been observed 
[93]. 
The coagulation cascade is activated in CSU and 
involves both the extrinsic and intrinsic pathways [94–96]. 
Tissue factor over-expressed by eosinophils that are 
activated via CD23, the low affinity IgE receptor, has been 
identified as a trigger [88, 97]. Sera from CU patients have 
been demonstrated to activate mast cell degranulation in an 
IgE- and IgG-independent manner and to increase vascular 
permeability [98]. However, the identity and function of 
these serum factors need yet to be identified. Interestingly, 
PAF may induce whealand-flare reactions independent of 
histamine release and mast cell degranulation [99]. 
Association of Urticaria with Autoimmunity and Infection 
There is increasing evidence that autoimmunity plays a 
causative role in CSU [9]. Type I (IgE-autoantibodies to 
autoantigens, e.g., thyroperoxidase (TPO)) and type II 
(IgG-autoantibodies to IgE or FcεRI) autoimmunity seem 
to be relevant in distinct CSU subpopulations rather than 
the same patients. Arguments supporting this concept are 
(1) the identification of two distinct subgroups with either 
low or high titers of anti-TPO IgE-antibodies (IgEanti-
TPOlow and IgE-anti-TPOhigh), (2) the absence of a 
correlation between IgE-autoantibodies and ASST 
response, (3) the correlation of IgG- but not 
IgEautoantibodies with disease activity/severity, and (4) 
different tempi of response to omalizumab [9]. In 
cholinergic urticaria, a hypersensitivity to sweat substances 
leaking from syringeal ducts to the dermis as well as an 
activation of mast cells by acetylcholine that is released by 
nerve cells but may not bind to its receptor because of 
reduced expression are discussed as main pathogenic 
mechanisms [100]. 
A recent meta-analysis confirmed the association of CU 
with thyroid autoimmunity reporting a higher prevalence of 
positive thyroid autoantibodies in patients with urticaria 
than non-urticaria controls (OR 6.55) [101]. The presence 
of anti-TPO-IgE is found in up to 54% of the CU patients 
[102], and a recent study suggested an autoallergic mast 
cell activation by anti-TPO-IgE [103]. 
The role of Helicobacter pylori (Hp) in CSU has 
controversially been discussed. Currently, it seems obvious 
that the prevalence of Hp infection is not increased in CSU 
patients, the effect of standard CSU treatment does not 
depend on Hp status, and Hp eradication does not have any 
additional beneficial effect on CSU [104]. A recent study 
Clinic Rev Allerg Immunol 
 
showed an association with previous HHV-6 infection, 
persistent viral gene expression, and replication with CSU 
[105]. A systematic review on internal parasites revealed 
that CSU patients were more often diagnosed with 
protozoa, e.g., Blastocystis hominis, and had a significantly 
higher risk of Toxocara seropositivity and Anisakis 
simplex sensitization as compared to healthy controls 
[106]. 
Therapy 
Guidelines for Urticaria Management 
According to current recommendations, the aim is a 
complete symptom control as safe as possible [2]. All 
factors identified to trigger urticaria in a certain individual 
should be avoided. As first-line therapy, second-
generation, non-sedating H1-antihistamines are used. Dose 
escalation up to fourfold dosage of antihistamines serves as 
second-line strategy. In case symptoms persist, an add-on 
of omalizumab, ciclosporin, or montelukast is 
recommended [2]. The American guidelines on urticaria 
management slightly differ from the European treatment 
standards [1]. Here, we will discuss new aspects in the 
management of urticaria and novel approaches. Use of 
Non-Sedating Antihistamines 
Antihistamines act as inverse agonist of the histamine (H) 
1 receptor and thus stabilize its inactive conformation 
[107]. Antihistamines may be up-dosed fourfold to the 
recommended standard dose. A questionnaire-based 
analysis revealed that patients who had up-dosed 
antihistamines reported a significant added benefit from 
taking two to four tablets daily while the number of reports 
of unwanted effects and sedation following updosing was 
not significantly different from those reported for standard 
doses [108]. In patients with cold contact urticaria, up-
dosing of bilastine resulted in a significantly better 
effectiveness without evidence of increased sedation with 
dose escalation [109]. Since sedating antihistamines added 
on to second generation antihistamines had no additional 
effects on CSU, but significantly increased daytime 
somnolence, they are not recommended for urticaria 
therapy anymore [110]. Treatment of Children with 
Urticaria 
Analogous to the adult patients, the same first-line therapy 
and up-dosing of non-sedating second generation 
antihistamines (weight adjusted) should be applied in 
children (2). Preferably, substances with proven efficacy 
and safety, e.g., cetirizine, desloratadine, and fexofenadine, 
should be used (2). Further steps have to be considered on 
an individual basis (2). 
Omalizumab 
The anti-IgE antibody omalizumab has been proven an 
efficacious and a well-tolerated therapy in patients with 
CSU refractory to antihistamines [111]. Recent 
publications also show its efficacy and safety in CIndUs, 
even though randomized controlled trials are still lacking 
[112, 113]. So far, the mechanisms of action of 
omalizumab are not fully understood. A recent review 
summarized potential mechanisms that include reducing 
mast cell activation, reversing basopenia, and improving 
basophil IgE receptor function, reducing the activity of IgG 
autoantibodies against FcεRI and IgE, of 
IgEautoantibodies against an antigen or autoantigen as well 
as of intrinsically Babnormal^ IgE, and decreasing 
coagulation abnormalities associated with disease activity 
[10, 79]. Omalizumab 300 mg every 4 weeks achieves fast 
responses and sustained effects [114] and significantly 
reduces the incidence of angioedema [115]. Patients with 
positive basophil histamine release assay and ASST tend to 
have a slow response to omalizumab therapy suggesting 
that omalizumab acts via reducing FcεRI expression [116]. 
An omalizumab treatment for 6 months might not be 
sufficient to control the disease [117]. Of note, retreatment 
of patients with CSU and/or CIndUs who initially 
responded to omalizumab, and experienced a relapse after 
suspending it, is considered as effective and safe as first 
treatment [118]. In case of a long-term therapy being 
required, a reduction of omalizumab dosage to 150 mg 
and/or extension of application interval is recommended 
[119]. 
Ciclosporin 
Ciclosporin is known to reduce the histamine release of 
both mast cells and basophils and affect Tcell activity. 
Based on the evidence of several randomized controlled 
trials, it is recommended as a third-line therapy [2]. 
Because of their better efficacy, ciclosporin and 
omalizumab have been favored over montelukast [120]. 
However, the safety profile of omalizumab was superior to 
that of other systemic therapies for urticaria including 
ciclosporin [121]. 
    
 
Inhibition of Tumor Necrosis Factor-α 
Increased levels of TNF-α in skin samples of CU are the 
rational for the use of anti-TNF-α therapy in 
histamineresistant CU. A single center retrospective 
observational study reported that upon therapy with TNF-α 
inhibitors, a total of 15 of 25 (60%) patients with refractory 
CU achieved a complete or almost complete resolution of 
symptoms [122]. 
Novel Therapeutic Approaches 
Recent research has improved our understanding of the 
pathogenesis of urticaria, in particular about the cells and 
mediators involved, signaling pathways, triggers, and 
associated autoimmune and infectious phenomena. Thus, a 
broad spectrum of potential therapeutic targets has been 
identified. The most promising recent strategies have been 
summarized 
[123]: 
– The development of more efficient antibodies 
targeting IgE and IgE receptor 
– Blocking the recruitment and activation of 
inflammatory cells 
– Inhibiting mast cell activation by blocking signaling 
pathways 
– Blocking pro-inflammatory cytokines and neuro-
peptides 
– Targeting complement C5a and C5a receptor 
– Supplementing vitamin D 
Currently registered clinical trials for urticaria therapy 
are given in Table 3. 
Outlook 
As this review demonstrates, immense progress has been 
made in understanding the pathogenesis and management 
of urticaria over the last decade. The launch of omalizumab 
has not only fundamentally improved urticaria treatment, it 
has also stimulated research in the field. So far, the causes 
and mechanisms of mast cell activation in urticaria patients 
have not completely been understood. Expanding our 
knowledge on urticaria pathogenesis, its genetics and 
phenotypes will have a direct impact on clinical praxis 
toward a personalized medicine and the development of 
novel therapies. 
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Target Drug name Mechanism Phase ClinicalTrials. 
gov 
IgE Ligelizumab Humanized monoclonal antibody targeting Cε3 
domain of IgE [124] 
Phase 
2b 
NCT02477332 
 Quilizumab Humanized monoclonal antibody targeting 
M1-prime segment of membrane bound IgE on 
IgE-switched B cells, IgE memory B cells and 
plasmablasts [125] 
Phase 
2 
NCT01987947 
Syk GSK2646264 Potent and selective topical Syk inhibitor [123] Phase 
1 
NCT02424799 
CRTh2 AZD1981 CRTh2 antagonist [123] Phase 
2a 
NCT02031679 
IL-1β Canakinumab Human monoclonal anti-IL 1β antibody [126] Phase 
2 
NCT01635127 
 Rilonacept Dimeric fusion protein composed of ligand binding 
domain of IL-1 receptor and IL-1R accessory 
protein bound to IgG1 [126] 
Phase 
2 
NCT02171416 
Vitamin 
D3 
 Supplementation because of reduced vitamin D 
levels in CU patients [127] 
Phase 
3 
NCT02873364 
Table 3 Novel approaches for 
the treatment of urticaria 
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